The competition is Eli Lilly... NVO in better spot this week then last week, but still second fiddle to Eli Lilly.... they are slowly losing market share because of the simple reason that Ozempic just isn't as good as Mounjaro, and suing Hims into the ground doesn't change that.
Wouldn’t you be better off buying $NVO calls? Took a huge dip after earnings due to forecasting increased competition, but that competition just folded thanks to FDA (someone please reassure me that my April 65$ calls won’t expire worthless)
I see. Somehow I thought they were selling NVO pills, saw the headline and thought NVO had pulled their products from HIMS. Didn't realize they had a competing pill